Nanobiotix Shares Surge 32.54% in One Week

Significant Weekly Gain

The stock closed on Friday at €22.40, up 32.54% from the previous Monday when it was trading at €16.90. This performance starkly contrasts with the downturn in benchmark indices, with the SBF 120 losing 1.75% and the CAC 40 down 1.72% over the same period. The movement was primarily concentrated in the middle of the week: after a quiet start on Monday and Tuesday around €18, the stock jumped more than 21% on Wednesday to reach €22.20, before hitting a peak of €23.90 on Thursday, its technical resistance level, and then stabilizing on Friday. Trading volumes significantly increased, with nearly 1.36 million shares traded on Wednesday, more than triple the average seen at the beginning of the week. This upward momentum is part of an exceptional long-term trend, with the stock posting a 401.1% increase over one year and 378.1% over three months.

Clinical Data Drives Growth

This acceleration originated from the release on Tuesday, October 1, of initial Phase 1 clinical data for the treatment JNJ-1900 (NBTXR3) in patients with esophageal adenocarcinoma. The study, conducted at the MD Anderson Cancer Center, showed a disease control rate of 85% and an objective response rate of 69% across 13 patients, with six complete remissions and three partial remissions. The treatment was well tolerated, and the recommended dose for Phase 2 was established. These results, presented at the annual meeting of the American Society for Radiation Oncology, were described as promising by several analysts. Concurrently, on Monday, October 6, Jefferies bank reaffirmed its buy recommendation on the stock and raised its price target from €18 to €21, acknowledging that the stock had already made significant gains but suggesting that potential for further upside remains, linked to positive publications about the candidate product applied to a wide range of solid tumors.